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Introduction: The characteristics of different types of epidermal 
growth factor receptor (EGFR) gene mutations in non–small-cell 
lung cancer (NSCLC) are not extensively studied. The distribution of 
EGFR mutations is known, with the most frequent in exon 19 (dele-
tions) or exon 21 (point mutations). Aberrations in exon 18 or 20 
are infrequently found. Point mutations in exon 20 confer resistance 
against tyrosine kinase inhibitors (TKIs), whereas the effect of the 
rare exon 20 insertions is, to a lesser extent, known. We present clini-
copathological characteristics of patients with EGFR mutations in 
the four exons, with emphasis on exon 20 positive patients.
Methods: NSCLC patients who tested positively for EGFR muta-
tions at the Oslo University Hospital, Oslo, Norway in the period 
between May 2010 and February 2012 were selected. Clinical infor-
mation was collected for mutated patients, and response information 
for patients with exon 20 insertions treated with TKI is reported.
Results: Of 119 patients with EGFR mutation, 62.2% were women. 
The median age was 66.0 years. The frequency of exon 18, 19, 20, 
and 21 was 7%, 45%, 7%, and 38%, respectively. Four patients 
(3.3%) had double mutations, and exon 20 was involved in three 
of these. Seven of 11 exon 20 positive patients were treated with 
TKI. All five single-mutated exon 20 positive TKI-treated patients 
had progressive disease at first evaluation, whereas both TKI-treated 
exon 20 involving double-mutated patients had partial response.
Conclusion: Exon 20 mutations seem to confer insensitivity to TKI 
treatment.
Key Words: Epidermal growth factor receptor mutation, Lung can-
cer, Epidermal growth factor receptor tyrosine kinase inhibitors, 
Sensitivity, Gefitinib, Erlotinib.
(J Thorac Oncol. 2012;7: 1471–1473)
Metastatic non–small-cell lung cancer (NSCLC) is invari-ably a deadly disease. Nevertheless, the aggressiveness is 
variable, with differences in both the natural course and in treat-
ment effects. The presence of mutations in the kinase domain of 
epidermal growth factor receptor (EGFR) gene has been regarded 
as both a positive prognostic and predictive marker, and most 
EGFR mutation-positive patients respond well to tyrosine kinase 
inhibitors (TKIs) such as gefitinib or erlotinib.1,2 However, it is 
now increasingly clear that not all EGFR mutations confer sen-
sitivity to TKIs, and, especially, point mutations in exon 20 are 
regarded as markers of resistance to this kind of therapy.3–6 Not 
much is known about the response in the presence of other low-
frequent mutations within the kinase domain of EGFR. Here we 
report the clinicopathological characteristics of EGFR-mutated 
patients and the selective treatment responses of exon 20 muta-
tions in an unselected material of mutation-positive patients.
PATIENTS AND METHODS
In Norway, all patients diagnosed with NSCLC since 
May 2010 have been recommended for testing for the pres-
ence of EGFR mutations. Approximately 900 tests are now per-
formed every year at our institution, Oslo University Hospital, 
Oslo, Norway. Mutation analysis of EGFR exons 18 to 21 is 
performed using the TheraScreen EGFR mutation kit (DxS, 
Manchester, United Kingdom). The assay is designed to detect 
28 specific mutations in the EGFR gene by real-time polymerase 
chain reaction. It enables the detection of 19 distinguished dele-
tions in exon 19, L858R, L861Q, G719X, S768I, and three 
insertions in exon 20. Assays were carried out according to the 
manufacturer’s protocol and by using the Roche LightCycler 
480 (Roche Diagnostics, Mannheim, Germany) real-time 
polymerase chain reaction system. Data analyses were per-
formed using the LightCycler Adapt software (LightCycler 480 
Software, v1.5). Some samples were analyzed using denaturing 
high-performance liquid chromatography followed by sequenc-
ing as previously described.7 We retrospectively reviewed 
patients who tested positive for EGFR mutations between May 
2010 and February 2012 at our institution.
RESULTS
A total of 119 patients testing positive for EGFR muta-
tions were identified; 74 women (62.2%) and 45 men (37.8%). 
The median age was 66.0 years, and 1-year overall survival 
after time of tissue sampling was 84.2% whereas median over-
all survival from sampling was 38.7 months. See Table 1 for 
differences in frequency, sex, and age among the four main 
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mutation types. Four patients had more than one mutation: two 
had G719X, S768I, one had G719X, L861Q, and one had del19, 
T790M. This latter patient was sampled upon resistance after 11 
months of TKI therapy (no pretreatment sample is available); all 
the other exon 20 positive patients were sampled before starting 
systemic therapy. All exon 20 positive patients were whites.
Seven of the 11 exon 20 positive patients have been 
treated with TKIs, all of whom have been response evaluated. 
The del19-, T790M-positive patient, sampled at progression, 
had partial response and was treated with TKI for 11 months 
until progression. One patient with double mutation (S768I, 
G719X) has now been on treatment for 14 months with a par-
tial response. The other five patients have had progressive dis-
ease at evaluation after 1 to 3 months of treatment. Details of 
the 11 patients are listed in Table 2.
DISCUSSION
We find a distribution of the main mutations in the 
EGFR gene comparable with that in other findings,8 with 
approximately 85% of aberrations found in exons 19 and 21. 
In our material, 11 of 123 EGFR-mutations (8.9%) were found 
in exon 20, and most of these were insertions. Interestingly, in 
three of the four patients with double mutations, one of the 
mutations was found in exon 20.
The finding that mutations in the EGFR gene predict 
effect of tyrosin kinase inhibitors has led to a paradigm shift 
in lung cancer care. In Norway, all new cases of NSCLC are 
tested for mutations in exon 18 to 21. Mutation-positive 
advanced cases are offered TKI treatment in first or second 
line. However, it is increasingly clear that not all mutations 
confer sensitivity to TKIs. As shown, of the six response-
evaluated patients with mutations in exon 20 (excluding the 
one with T790M mutation) only the one with a concurrent 
mutation in exon 18 has been treated beyond first evalua-
tion. Even though mutations in exon 20 are most uncom-
mon—only 122 cases were found in a recent review4—the 
awareness that these might confer sensitivities to first- 
generation TKIs comparable with wild-type tumors should 
be emphasized. The exact mechanism of the nonsensitiv-
ity is not clarified, and the clinical impact has not been 
systematically investigated in any study.4 Interestingly, in 
this exon 20 positive group only three of 10 patients with 
known smoking status were never-smokers, compared with 
eight of 18 patients in an unselected Norwegian EGFR-
positive cohort.7
We have found clinicopathological differences between 
the main EGFR-mutation types in NSCLC. Even though we 
report a limited number of exon 20 positive tumors, this 
adds to a relatively scarce literature on the insensitivity of 
this mutation type toward erlotinib or gefitinib and under-
scores that patients harboring this mutation type should be 
considered for conventional chemotherapy and not first-gen-
eration TKIs. Of note, the novel second- or third-generation 
TABLE 1.  Differences in Frequency, Sex, and Age Among 
the Main Mutation Types
Exon Number (%) Females (%) Median Age (Yrs) (Range)
18 8 (6.7) 75.0 71.4 (56.6–79.8)
19 54 (45.4) 61.1 61.6 (37.8–88.7)
20 8 (6.7) 75.0 70.1 (55.3–78.1)
21 45 (37.8) 60.0 69.0 (48.1–83.9)
Double mutations 4 (3.3) 50.0 69.3 (48.6–77.5)
Characteristics of patients in the main EGFR-mutation categories. Three double 
mutants involved exon 20. 
Exon 19-positive patients were significantly younger than patients who were exon 
21-positive (p = 0.001).
TABLE 2.  Characteristics of Patients in the Main EGFR-Mutation Categories
ID Histology Mutation Type Sex Age 
(Yrs)
Stage Smoking 
Status
Prior Therapy TKI Type Time on 
Treatment 
(Mos)
Response
1 AC Ins F 56 IV Never Carboplatin/vinorelbin Erlotinib 1 PD
2 AC Ins (c.2311_2319dup; 
p.Asn771_His773dup)
M 62 IV Former Carboplatin/vinorelbin None N/A N/A
3 AC Ins F 68 IV Former Carboplatin/vinorelbin Erlotinib 3 PD
4a AC T790M+del 19 F 48 IV Former Carboplatin/vinorelbin Erlotinib N/A N/A
5 BAC Ins (c.2309_2310ins9bp; 
Val769_Asp770insAlaSerVal)
F 72 Relapse after 
surgery
Never Surgery Gefitinib 2 PD
6 AC S768I + G719X F 68 I Former Surgery None N/A N/A
7 AC S768I + G719X M 70 IV Unknown None Gefitinib 14 PR
8 AC S768I F 73 IV Former Carboplatin/vinorelbin Erlotinib 1 PD
9 AC Ins M 78 IV Former None Gefitinib 3 PD
10 SCC Ins F 63 IIa Current Surgery None N/A N/A
11 AC Ins F 76 IIa Never Surgery None N/A N/A
Characteristics of 11 patients with mutations in exon 20 of EGFR.
aThis patient was sampled for EGFR-mutation analysis at progression after 11 months of erlotinib treatment. IDs 5, 10, and 11 have been partially reported previously (as T107, 
T94, and T104, respectively in 7).
AC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SCC, squamous cell carcinoma; Ins, insertion in exon 20 (detailed or not specified); F, female; M, male; N/A, not 
applicable; PD, progressive disease; PR, partial response.
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EGFR TKIs may have better activity against exon 20 posi-
tive tumors and may therefore become an option for patients 
with such tumors.
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